Data protection Impressum

Healthcare

The CHUV in Lausanne has inaugurated the state-of-the-art Swiss BioMotion Lab, which offers innovative solutions for the study and treatment of osteoarthritis through cutting-edge motion analysis.

CHUV inaugurates Swiss BioMotion Lab for advanced osteoarthritis research and treatment

23 September 2024

HAYA Therapeutics has announced a multi-year collaboration with Eli Lilly, potentially earning up to USD 1 billion in milestone payments to advance RNA-guided therapies for obesity and metabolic disorders.

HAYA Therapteutics enters major collaboration to advance RNA-based drug discovery

17 September 2024

LEM Surgical, a leader in surgical robotics, has opened a state-of-the-art 19,400-square-foot headquarters in Bern, Switzerland.

LEM Surgical unveils new headquarters in Bern to advance surgical robotics

3 September 2024

Biotech Vandria has raised an additional CHF 14 million to accelerate the development of innovative treatments for age-related and chronic diseases, bringing its total Series A financing to CHF 28.3 million.

Vandria secures over CHF 14 million to advance age-related disease therapies

3 September 2024

Four pioneering Geneva-based start-ups have received funding from the FONGIT Innovation Fund (FIF) to drive innovation in the life sciences and ICT sectors.

FONGIT Innovation Fund finances four ICT and life sciences start-ups from Geneva

2 September 2024

Top Stories Western Switzerland

Business environment

Top Stories from Western Switzerland (August 2024)

30 August 2024

Release Therapeutics has raised CHF 3.3 million in seed funding to advance its innovative approach to treating metachromatic leukodystrophy (MLD), a rare genetic disorder affecting young children.

Release Therapeutics secures CHF 3.3 million to advance MLD research

13 August 2024

CSEM, along with start-ups Impli and Yalosys, has developed CERES, an implantable biosensor for real-time fertility hormone monitoring.

CSEM develops a pioneering implant to support reproductive medicine

7 August 2024

AC Immune’s ACI-35.030 (now called JNJ-2056), an active-immunotherapy candidate targeting the pathologic form of the Tau protein, has received Fast Track designation from the U.S. Food and Drug Administration (FDA).

AC Immune receives FDA Fast Track designation for Alzheimer’s disease therapy

6 August 2024

Geneva-based Agora Care has closed a financing round of CHF 2.2 million to support its expansion into the US market and increase patient enrollment in Switzerland and Europe.

Medical imaging specialist Agora Care secures CHF 2.2 million for US market expansion

5 August 2024

1 … 8 9 10 11 12 13 14 15 16 … 21